Loading...
Loading...
CATX| Name | Value |
|---|---|
| Revenues | 1.9M |
| Cost of Revenue | 1.4M |
| Gross Profit | 0.5M |
| Operating Expense | 11.0M |
| Operating I/L | -10.5M |
| Other Income/Expense | -0.0M |
| Interest Income | 0.2M |
| Pretax | -10.1M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -10.4M |
Perspective Therapeutics, Inc. develops, manufactures, and markets isotope-based medical products and devices for cancer treatment. Its flagship product, CS-1 Cesium-131 brachytherapy seeds, is used for various cancer types including prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. The company generates revenue by selling these products to facilities and physician practices that utilize surgical facilities for cancer treatment.
